Diffuse Large B Cell Lymphoma Clinical Trials in Shanghai, Shanghai Municipality
13 recruitingShanghai, Shanghai Municipality, China
Showing 1–13 of 13 trials
Recruiting
Phase 3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Diffuse Large B Cell Lymphoma
Merck Sharp & Dohme LLC1,046 enrolled246 locationsNCT06717347
Recruiting
Phase 2Phase 3
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Diffuse Large B Cell LymphomaDLBCL
Merck Sharp & Dohme LLC290 enrolled116 locationsNCT05139017
Recruiting
Phase 3
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Diffuse Large B Cell Lymphoma
Genmab360 enrolled177 locationsNCT06508658
Recruiting
Phase 2
Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)
Diffuse Large B Cell Lymphoma
Sun Yat-sen University42 enrolled2 locationsNCT06517511
Recruiting
Phase 1Phase 2
Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.90 enrolled25 locationsNCT06829771
Recruiting
Phase 2
Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
Diffuse Large B Cell Lymphoma
Ruijin Hospital152 enrolled1 locationNCT06803693
Recruiting
Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET
Diffuse Large B Cell LymphomaDLBCL
Fudan University300 enrolled1 locationNCT07070648
Recruiting
Phase 2
Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation
Diffuse Large B Cell Lymphoma
Fudan University130 enrolled1 locationNCT07001540
Recruiting
Real-World Study of DLBCL With Different Genetic Subtypes
DLBCL - Diffuse Large B Cell LymphomaLymphoma
Ruijin Hospital10,000 enrolled1 locationNCT06026488
Recruiting
Phase 2
R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse
Diffuse Large B Cell Lymphoma
Fudan University83 enrolled2 locationsNCT05257018
Recruiting
Phase 2
Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma
Diffuse Large B Cell Lymphoma
Ruijin Hospital76 enrolled1 locationNCT05348213
Recruiting
Phase 2
Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL
Diffuse Large B-cell Lymphoma RecurrentDiffuse Large B Cell Lymphoma Refractory
RenJi Hospital20 enrolled1 locationNCT06033820
Recruiting
Phase 3
Genotype-guided Treatment in DLBCL
Diffuse Large B Cell Lymphoma
Ruijin Hospital1,100 enrolled1 locationNCT05351346